HeartBeam, Inc. (NASDAQ:BEAT) Q1 2024 Earnings Call Transcript

This is an existing, and I would say, demonstrated value of combining the power of VECG with power of AI. That, combined with the availability of a 12-lead ECG, makes for an offering that will make a difference, first and foremost, for the patient, but also for the physician, who will now be equipped with 12-lead synthesized ECGs and a powerful diagnostic suggestion tool that stems from VECG application to the AI algorithms.

Brooks Hamilton: All right. It looks like that’s it for the webcast questions. I’ll now turn the call back over to Dr. Vajdic for his closing remarks.

Branislav Vajdic: So, at this point, we’d like to conclude this conference. We very much appreciate your attendance and look forward to continued dialogue with our investors. And if we have not covered all questions today, please do not hesitate to contact our IR firm, MZ Group, for further interactions. Thank you again and have a good day.

Operator: The conference is now concluded. Thank you for attending today’s presentation. You may now disconnect.